Zevra Therapeutics, Inc.
ZVRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $483 | $405 | $448 |
| - Cash | $54 | $48 | $37 | $34 |
| + Debt | $62 | $62 | $62 | $60 |
| Enterprise Value | – | $497 | $430 | $474 |
| Revenue | $26 | $26 | $20 | $12 |
| % Growth | 0.7% | 26.9% | 69.4% | – |
| Gross Profit | $25 | $14 | $19 | $11 |
| % Margin | 94% | 52.2% | 93.4% | 88.7% |
| EBITDA | $1 | $81 | $2 | -$17 |
| % Margin | 5.6% | 311.3% | 8.3% | -137.2% |
| Net Income | -$1 | $75 | -$3 | -$36 |
| % Margin | -5.4% | 288.7% | -15.2% | -296.8% |
| EPS Diluted | -0.01 | 1.364 | -0.057 | -0.67 |
| % Growth | -100.7% | 2,479.9% | 91.4% | – |
| Operating Cash Flow | $5 | -$4 | -$8 | -$16 |
| Capital Expenditures | -$1 | -$0 | -$0 | $0 |
| Free Cash Flow | $4 | -$4 | -$8 | -$16 |